Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis
The Oncologist · 05.07.2024 · 29 (7) · 566-574
DOI: 10.1093/oncolo/oyae064 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 24.04.2024. Verfasst von Alexis LeVee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, United States. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antibodies, Monoclonal, Humanized, Neoadjuvant Therapy. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The addition of pembrolizumab (pembro) to neoadjuvant chemotherapy (NAC) is standard of care for the treatment of early triple-negative breast cancer (TNBC) after KEYNOTE-522 trial demonstrated improved pathologic complete response (pCR) rates with the combination. However, the optimal treatment strategy for TNBC remains uncertain as questions persist about which patients benefit from pembro and the best treatment schedule and regimen. We identified real-world clinical characteristics and treatment variables associated with response to NAC plus pembro.
Methods
Patients with early TNBC treated with NAC plus pembro between February 2020 and September 2023 were identified. Univariate and multivariate analysis was performed using logistic regression to identify factors associated with pCR. Cox proportional hazard prediction models were used to identify predictors of invasive disease-free survival and overall survival in this cohort.
Results
A pCR was achieved in 75 (63.6%) of 118 patients. Age at diagnosis (P = .04), Ki-67 (P = .004), duration from start of pembro to surgery (P = .006) and NAC to surgery (P = .01), number of cycles of pembro (P = .04) and NAC (P = .02), and completion of at least 8 cycles of pembro (P = .015) and NAC (P = .015) were each significantly associated with pCR in univariate analysis. In multivariate analysis, patients younger than 55 years at time of diagnosis (vs age > 55 years) and those completing at least 8 cycles of pembro remained predictive of pCR (OR’s 2.50, 2.49, P = .035 and .037, respectively).
Conclusions
In this real-world analysis of patients with TNBC treated with NAC plus pembro, younger age and the completion of at least 8 cycles of pembrolizumab were associated with pCR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, United States.
- Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX, United States.
ORCID-Profile: Alexis LeVee, Nora Ruel
Zitieren
APA
LeVee, A., Wong, M., Flores, S., Ruel, N., McArthur, H., Waisman, J., & Mortimer, J. (2024). Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis. The Oncologist, 29(7), 566-574. https://doi.org/10.1093/oncolo/oyae064
Vancouver
LeVee A, Wong M, Flores S, Ruel N, McArthur H, Waisman J, et al. Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis. The Oncologist. 2024;29(7):566-574. doi:10.1093/oncolo/oyae064
BibTeX
@article{LeVee2024,
author = {LeVee, Alexis and Wong, Megan and Flores, Sarah and Ruel, Nora and McArthur, Heather and Waisman, James and Mortimer, Joanne},
title = {Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {7},
pages = {566--574},
doi = {10.1093/oncolo/oyae064}
}
EUVIMED